Mei Pharma Stock Buy Hold or Sell Recommendation
| MEIP Stock | USD 3.25 0.06 1.81% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding MEI Pharma is 'Strong Hold'. Macroaxis provides MEI Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MEIP positions. The advice algorithm takes into account all of MEI Pharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting MEI Pharma's buy or sell advice are summarized below:
Real Value 8.35 | Target Price 23.67 | Hype Value 3.43 | Market Value 3.25 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell MEI Pharma given historical horizon and risk tolerance towards MEI Pharma. When Macroaxis issues a 'buy' or 'sell' recommendation for MEI Pharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
MEI |
Execute MEI Pharma Buy or Sell Advice
The MEI recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on MEI Pharma. Macroaxis does not own or have any residual interests in MEI Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute MEI Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
MEI Pharma Trading Alerts and Improvement Suggestions
| MEI Pharma generated a negative expected return over the last 90 days | |
| MEI Pharma has high historical volatility and very poor performance | |
| MEI Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 48.82 M. Net Loss for the year was (31.84 M) with profit before overhead, payroll, taxes, and interest of 48.82 M. | |
| MEI Pharma currently holds about 153.25 M in cash with (52.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15. | |
| Latest headline from investing.com: MEI Pharma reports progress in colorectal cancer study |
MEI Pharma Returns Distribution Density
The distribution of MEI Pharma's historical returns is an attempt to chart the uncertainty of MEI Pharma's future price movements. The chart of the probability distribution of MEI Pharma daily returns describes the distribution of returns around its average expected value. We use MEI Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of MEI Pharma returns is essential to provide solid investment advice for MEI Pharma.
| Mean Return | -0.78 | Value At Risk | -7.27 | Potential Upside | 5.26 | Standard Deviation | 3.58 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of MEI Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
MEI Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MEI Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MEI Pharma backward and forwards among themselves. MEI Pharma's institutional investor refers to the entity that pools money to purchase MEI Pharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2023-12-31 | 26.9 K | Northern Trust Corp | 2023-12-31 | 24.8 K | State Street Corporation | 2023-12-31 | 17.8 K | Susquehanna International Group, Llp | 3123-12-31 | 13.5 K | Royal Bank Of Canada | 2023-12-31 | 11.9 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 10.9 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 5.9 K | Group One Trading, Lp | 2023-12-31 | 5.7 K | Newbridge Financial Services Group, Inc. | 2023-12-31 | 2 K | Anson Funds Management Lp | 2023-12-31 | 1.1 M | Cable Car Capital Llc | 2023-12-31 | 611.4 K |
MEI Pharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 2.7M | (3.8M) | 7.2M | 1.2M | 1.0M | 615.0K | |
| Other Non Cash Items | 23.1M | (18.1M) | (19.8M) | 1.4M | 1.3M | 1.4M | |
| Capital Expenditures | 894K | 708K | 479K | 35K | 40.3K | 38.2K | |
| Net Income | (46.0M) | (50.6M) | (54.5M) | (31.8M) | (28.7M) | (30.1M) | |
| End Period Cash Flow | 12.3M | 8.5M | 15.7M | 16.9M | 19.4M | 14.9M | |
| Free Cash Flow | 33.4M | (32.7M) | (49.2M) | (52.5M) | (47.3M) | (44.9M) | |
| Depreciation | 109K | 285K | 326K | 386K | 443.9K | 466.1K | |
| Change To Inventory | 2.3M | (15.7M) | 2.5M | (10.0M) | (9.0M) | (8.5M) | |
| Change To Netincome | 7.0M | (7.9M) | (11.5M) | 3.9M | 3.5M | 3.7M | |
| Investments | (105.4M) | 25.4M | 7.4M | 53.7M | 61.7M | 64.8M |
MEI Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to MEI Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that MEI Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a MEI stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.79 | |
β | Beta against NYSE Composite | -0.1 | |
σ | Overall volatility | 3.36 | |
Ir | Information ratio | -0.24 |
MEI Pharma Volatility Alert
MEI Pharma exhibits very low volatility with skewness of -0.43 and kurtosis of 0.76. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure MEI Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact MEI Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.MEI Pharma Fundamentals Vs Peers
Comparing MEI Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze MEI Pharma's direct or indirect competition across all of the common fundamentals between MEI Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as MEI Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of MEI Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing MEI Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare MEI Pharma to competition |
| Fundamentals | MEI Pharma | Peer Average |
| Return On Equity | 0.37 | -0.31 |
| Return On Asset | 0.083 | -0.14 |
| Profit Margin | 0.27 % | (1.27) % |
| Operating Margin | 0.21 % | (5.51) % |
| Current Valuation | (25.8 M) | 16.62 B |
| Shares Outstanding | 6.66 M | 571.82 M |
| Shares Owned By Insiders | 0.53 % | 10.09 % |
| Shares Owned By Institutions | 47.57 % | 39.21 % |
| Number Of Shares Shorted | 7.83 K | 4.71 M |
| Price To Earning | 30.29 X | 28.72 X |
| Price To Book | 0.37 X | 9.51 X |
| Price To Sales | 0.30 X | 11.42 X |
| Revenue | 48.82 M | 9.43 B |
| Gross Profit | 48.82 M | 27.38 B |
| EBITDA | (37.98 M) | 3.9 B |
| Net Income | (31.84 M) | 570.98 M |
| Cash And Equivalents | 153.25 M | 2.7 B |
| Cash Per Share | 1.15 X | 5.01 X |
| Total Debt | 12.73 M | 5.32 B |
| Debt To Equity | 0.18 % | 48.70 % |
| Current Ratio | 6.84 X | 2.16 X |
| Book Value Per Share | 8.93 X | 1.93 K |
| Cash Flow From Operations | (52.48 M) | 971.22 M |
| Short Ratio | 0.30 X | 4.00 X |
| Earnings Per Share | 2.98 X | 3.12 X |
| Price To Earnings To Growth | 20.60 X | 4.89 X |
| Target Price | 23.0 | |
| Number Of Employees | 46 | 18.84 K |
| Beta | 0.64 | -0.15 |
| Market Capitalization | 21.65 M | 19.03 B |
| Total Asset | 120.81 M | 29.47 B |
| Retained Earnings | (406 M) | 9.33 B |
| Working Capital | 87.19 M | 1.48 B |
Note: Acquisition by Nicholas Glover of 87500 shares of MEI Pharma subject to Rule 16b-3 [view details]
MEI Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as MEI . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 640.05 | |||
| Daily Balance Of Power | (0.75) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 3.26 | |||
| Day Typical Price | 3.26 | |||
| Price Action Indicator | (0.04) | |||
| Period Momentum Indicator | (0.06) |
About MEI Pharma Buy or Sell Advice
When is the right time to buy or sell MEI Pharma? Buying financial instruments such as MEI Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 10.8M | 12.5M | 14.3M | 15.0M | Total Assets | 177.8M | 120.8M | 138.9M | 145.9M |
Use Investing Ideas to Build Portfolios
In addition to having MEI Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities ETFs Thematic Idea Now
Utilities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out MEI Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for MEI Stock analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is MEI Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MEI Pharma. If investors know MEI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MEI Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.98 | Revenue Per Share 10.903 | Quarterly Revenue Growth 6.48 | Return On Assets 0.083 | Return On Equity 0.368 |
The market value of MEI Pharma is measured differently than its book value, which is the value of MEI that is recorded on the company's balance sheet. Investors also form their own opinion of MEI Pharma's value that differs from its market value or its book value, called intrinsic value, which is MEI Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MEI Pharma's market value can be influenced by many factors that don't directly affect MEI Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MEI Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if MEI Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MEI Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.